Company: INTS
Filing Date: 2025-06-12
Form Type: 424B5
Source: 0001628280-25-031040
Chunk: 5

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-12
Form: 424B5
Chunk 5
---
 commercialize our product candidates;

• the timing or likelihood of regulatory filings and approvals;

• the ability of our research to generate and advance additional product candidates;

• the implementation of our business model, strategic plans for our business, product candidates and technology;

• our commercialization, marketing and manufacturing capabilities and strategy;

• the rate and degree of market acceptance and clinical utility of our system;

• our competitive position;

• our intellectual property position;

• developments and projections relating to our competitors and our industry;

• our ability to maintain and establish collaborations or obtain additional funding;

• our expectations related to the use of our cash and cash equivalents and investments;

• our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and

• other factors that may impact our financial results.

All of our forward-looking statements are as of the date of this prospectus supplement only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such

<div align='center'>S-2</div>

expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this prospectus supplement or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this prospectus supplement, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this prospectus supplement that modify or impact any of the forward-looking statements contained herein will be deemed to modify or supersede such statements in this prospectus supplement.

<div align='center'>S-3</div>

### PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This summary does not contain all the information that you should consider before investing in our securities. You should read the entire prospectus supplement and the accompanying prospectus carefully, including “Risk Factors” contained in this prospectus supplement and the accompanying prospectus, the financial statements incorporated by reference in this prospectus supplement and the accompanying prospect